TDIQ hydrochloride

Cat. No.: HY-W042920A: Ficha de datos Instrucciones de manejo
FAQs
Technical Support

TDIQ hydrochloride is an analog of Amphetamine with high affinity for α2-adrenergic receptor. TDIQ hydrochloride is a selective α2-adrenoceptor ligand with the K_i values of 75 nM, 95 nM, and 65 nM for α2A-, α2B-, and α2C-adrenergic receptors, respectively.

Para uso exclusivo en investigación. No vendemos a pacientes.

TDIQ hydrochloride Estructura química

No. CAS : 15052-05-8

Tamaño	Stock	Cantidad
1 mg	Obtener un presupuesto 3 - 4 Weeks 4 - 5 Weeks 5 - 6 Weeks 2 - 3 weeks	Estimated Time of Arrival: December 31
5 mg	Obtener un presupuesto 3 - 4 Weeks 4 - 5 Weeks 5 - 6 Weeks 2 - 3 weeks	Estimated Time of Arrival: December 31
10 mg	Obtener un presupuesto
50 mg	Obtener un presupuesto

Synthetic products have potential research and development risk.

or Consulta para venta a granel

* Seleccione Cantidad antes de agregar artículos.

This product is a controlled substance and not for sale in your territory.

Recomendaciones destacadas

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

Ver todos los productos específicos de isoformas Adrenergic Receptor:

Ver todas las isoformas

α adrenergic receptor β adrenergic receptor

Actividad biológica
Pureza y Documentación
Referencias
Revisión del cliente

Descripciòn	TDIQ hydrochloride is an analog of Amphetamine with high affinity for α2-adrenergic receptor. TDIQ hydrochloride is a selective α2-adrenoceptor ligand with the K_i values of 75 nM, 95 nM, and 65 nM for α2A-, α2B-, and α2C-adrenergic receptors, respectively^[1].
Peso molecular	213.66
Fòrmula	C₁₀H₁₂ClNO₂
No. CAS	15052-05-8
SMILES	C12=C(C=C3OCOC3=C2)CNCC1.Cl
Envío	Room temperature in continental US; may vary elsewhere.
Almacenamiento	Please store the product under the recommended conditions in the Certificate of Analysis.
Pureza y Documentación	Ficha de datos (269 KB) Instrucciones de manejo (2659 KB)
Referencias	[1]. Young R. TDIQ (5,6,7,8-tetrahydro-1,3-dioxolo [4,5-g]isoquinoline): discovery, pharmacological effects, and therapeutic potential. CNS Drug Rev. 2007 Winter;13(4):405-22. [Content Brief]